Community Contributor
Member since 2025
Views
20.8k Total number of views
Fair Values Set
290 Total number of fair values set
Comments
3 Total number of comments
Followers
3 Total number of followers

💊 I read the earnings calls and run the valuations so you don't have to 📉 Long-term investor, short-term heart rate 🏥 Building Red Candle Rx Fund. NFA

No link added
PLX logo
Protalix BioTherapeutics

Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth

As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more

View narrative
US$4.23
45.9% undervalued intrinsic discount
Fair Value
Revenue
14% p.a.
Profit Margin
20%
Future PE
29.15x
Price in 2028
US$5.11
US$37.42
289.1% overvalued intrinsic discount
Fair Value
Revenue
26.99% p.a.
Profit Margin
49%
Future PE
20x
Price in 2030
US$58.69
US$73.83
47.7% overvalued intrinsic discount
Fair Value
Revenue
14.51% p.a.
Profit Margin
4.33%
Future PE
18.91x
Price in 2028
US$97.27
US$152.71
38.7% undervalued intrinsic discount
Fair Value
Revenue
30.8% p.a.
Profit Margin
10%
Future PE
25x
Price in 2030
US$224.38
NKE logo
NIKE

A conservative outlook sees Nike's stock rolling towards a $100 mark within the next couple years

With pretty conservative estimates I am seeing Nike hitting at least $100 roughly in 3 years. However this is with a revenue growth of 2%.Read more

View narrative
US$96.6
59.5% undervalued intrinsic discount
Fair Value
Revenue
2% p.a.
Profit Margin
11.1%
Future PE
30x
Price in 2028
US$120.01
US$290.64
74.1% overvalued intrinsic discount
Fair Value
Revenue
31% p.a.
Profit Margin
8.03%
Future PE
34.27x
Price in 2035
US$688.05
US$228.21
50.7% overvalued intrinsic discount
Fair Value
Revenue
5.16% p.a.
Profit Margin
32.4%
Future PE
25x
Price in 2028
US$291.48